Oneness Biotech Co., Ltd. (4743) AI Stock Analysis

Oneness Biotech Co., Ltd.

(TPEx:4743)

Select Model

Rating:44Neutral

Price Target:TWD 44.00▼(-4.86% Downside)

Action:initiatedcoverage

Date:11/10/26

Strong balance sheet is the primary positive factor offering stability, while revenue volatility and cash burn limit financial strength. Weak technical momentum from price below moving averages and negative MACD further constrains the score, and elevated valuation multiples add pressure.

Positive Factors

Revenue ImprovementRecent revenue improvement indicates that Oneness Biotech is maintaining commercial traction despite its profitability challenges. Continued top-line expansion would broaden the revenue base, support operating leverage, and provide a foundation for improving earnings if margins stabilize over the coming quarters.

Negative Factors

Persistent UnprofitabilitySustained negative net margins show that revenue growth has not yet translated into an economically profitable operating model. Continued losses can restrict internally funded investment, weaken returns on capital, and leave future earnings dependent on meaningful improvement in pricing, mix, or operating costs.

Oneness Biotech Co., Ltd. (4743) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 22.51B
Dividend Yield: ―
Average Volume (3M): 1.34M
Price to Earnings (P/E): -102.6
Beta (1Y): 0.65
Revenue Growth: 14.79%
EPS Growth: 84.54%
Country: TW
Employees: 180
Sector: General
Sector Strength: 55
Industry: Biotechnology

Oneness Biotech Co., Ltd. Business Overview & Revenue Model

Company Description

Oneness Biotech Co., Ltd., headquartered in Taipei City, Taiwan, functions as a biopharmaceutical enterprise primarily dedicated to the discovery and advancement of novel therapeutic agents, in addition to selling pharmaceutical and health-related me...

Oneness Biotech Co., Ltd. Financial Statement Overview

Summary

Strong balance sheet with very low debt-to-equity provides stability and resilience, but extreme revenue volatility, persistent net losses, and negative cash flows create ongoing challenges.

Income Statement

32Negative

Balance Sheet

82Very Positive

Cash Flow

23Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	149.22M	129.12M	117.93M	86.78M	1.07B	65.77M
Gross Profit	57.37M	35.95M	63.03M	32.56M	844.39M	45.04M
EBITDA	-274.48M	-469.09M	-685.71M	-647.63M	253.19M	-193.72M
Net Income	59.65M	-1.04B	-1.17B	-1.31B	359.98M	-412.82M
Balance Sheet
Total Assets	11.27B	11.73B	13.66B	15.36B	15.58B	15.73B
Cash, Cash Equivalents and Short-Term Investments	5.43B	5.82B	7.02B	7.77B	8.05B	7.81B
Total Debt	352.21M	370.73M	406.35M	432.20M	263.45M	283.82M
Total Liabilities	872.67M	1.26B	859.65M	866.43M	700.38M	1.64B
Stockholders Equity	10.25B	10.33B	12.30B	14.05B	14.62B	14.02B
Cash Flow
Free Cash Flow	-190.51M	-470.89M	-398.86M	-512.23M	-970.19M	-389.19M
Operating Cash Flow	-174.55M	-448.93M	-345.58M	-422.18M	-881.00M	-288.89M
Investing Cash Flow	-2.34B	1.07B	544.16M	-4.82B	5.74B	59.54M
Financing Cash Flow	-15.52M	-12.49M	19.70M	386.58M	451.87M	344.67M

Oneness Biotech Co., Ltd. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:4743 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TW:4105	79Outperform	TWD 20.44B	12.48	―	5.48%	4.54%	-7.38%
TW:4728	76Outperform	TWD 21.13B	26.04	―	6.11%	12.50%	16.12%
TW:6620	70Outperform	TWD 20.83B	66.76	―	1.52%	―	―
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TW:4123	48Neutral	TWD 22.38B	23.82	―	6.15%	3.63%	―
TW:4743	44Neutral	TWD 22.59B	-102.60	―	―	14.79%	84.54%

* General Sector Average

Performance Comparison

TW:4743 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:4743	Oneness Biotech Co., Ltd.	46.25	-16.25	-26.00%
TW:4105	TTY Biopharm Company Limited	82.10	7.64	10.26%
TW:4123	Center Laboratories, Inc.	28.40	-5.63	-16.55%
TW:4728	SunMax Biotechnology Co. Ltd.	388.00	5.62	1.47%
TW:6586	CHO Pharma, Inc.	76.20	46.15	153.58%
TW:6620	Handa Pharmaceuticals Inc	136.50	17.95	15.14%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026

Oneness Biotech Co., Ltd. AI Stock Analysis